Takeda Pharmaceutical (TAK) Amortizatization of Intangibles (2018 - 2019)
Takeda Pharmaceutical (TAK) posted Amortizatization of Intangibles of -$953.4 million for Q3 2019, down 342.56% on a QoQ basis from -$215.4 million in Q3 2018, and down 342.56% year-over-year from $393.0 million in Q3 2018.
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Amortizatization of Intangibles (2018 - 2019) Analysis & Trends
Takeda Pharmaceutical has reported Amortizatization of Intangibles for 2 years, with the latest figure at -$953.4 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | - |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | 4.33 Mn |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | - |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | - |